Overview

Ribociclib and Spartalizumab in R/M HNSCC

Status:
Active, not recruiting

Trial end date:
2025-01-01

Target enrollment:

Participant gender:

Summary

This study examines the safety and efficacy of ribociclib (CDK 4/6 inhibitors) and spartalizumab (anti-PD1) in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Phase:

Phase 1

Details

Lead Sponsor:

National Taiwan University Hospital

Collaborator:

Novartis

Treatments:

Spartalizumab